Finance

Kazia Therapeutics

$10.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.41 (-3.91%) Today
+$0.42 (+4.17%) As of 12:36 PM UTC after-hours

Why Robinhood?

You can buy or sell KZIA and other stocks, options, and ETFs commission-free!

About KZIA

Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia. The listed name for KZIA is Kazia Therapeutics Limited American Depositary Shares.

CEO
James Garner
Employees
—
Headquarters
Sydney, New South Wales (NSW)
Founded
1994
Market Cap
122.98M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
190.57K
High Today
$10.76
Low Today
$10.08
Open Price
$10.76
Volume
139.40K
52 Week High
$15.85
52 Week Low
$2.47

Collections

KZIA Earnings

Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 9, Pre-Market

You May Also Like

NVGS
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure